Ketamine’s Distinct Short-Term Effects on Insomnia and Anxiety in TRD

Ketamine Rapidly Reduces Insomnia and Anxiety in TRD

Ketamine administration leads to significant short-term reductions in insomnia, anxiety, and depression among patients with treatment-resistant depression (TRD), according to a clinical trial published on October 6, 2026 (OpenAlex; ClinicalTrials.gov NCT00088699). Seventy-one adults with TRD received a single intravenous ketamine infusion (0.5 mg/kg), with symptom assessments at baseline and 24 hours post-treatment using the Montgomery–Åsberg Depression Rating Scale (MADRS), Hamilton Anxiety Rating Scale (HAM-A), and insomnia items from the Hamilton Depression Rating Scale (HAM-D). All three domains—depression, anxiety, and insomnia—showed statistically significant improvement within 24 hours of ketamine administration, with effect sizes (β) of –11.72 (depression), –7.87 (anxiety), and –0.89 (insomnia), all with P-values less than 0.001.

Distinct Mechanisms: Insomnia Improvement Is Not Tied to Mood or Anxiety

Improvements in insomnia following ketamine treatment occur independently of changes in depression or anxiety symptoms in TRD. While baseline insomnia was moderately correlated with anxiety (Spearman ρ = 0.36) and anxiety with depression (Pearson r = 0.39), changes in insomnia after ketamine were not significantly associated with changes in either depression or anxiety. In contrast, reductions in anxiety and depression were strongly linked (Spearman ρ = 0.61). This suggests that ketamine’s effect on sleep may involve distinct neurobiological pathways compared to its antidepressant and anxiolytic actions. Exploratory polysomnography data in this study further indicated short-term increases in total sleep time, slow-wave sleep, and sleep efficiency, as well as reduced sleep latency—objective markers supporting the subjective insomnia improvements. Notably, patients with more severe baseline insomnia experienced the greatest short-term sleep benefits, a detail that may inform patient selection in future trials.

Implications for Clinical Protocols and Research Design

These findings support the nuanced use of ketamine in psychiatric care, particularly for TRD patients with comorbid insomnia. The independence of insomnia improvement from mood and anxiety changes suggests that trial endpoints and clinical protocols should separately track sleep outcomes, rather than assuming they will mirror mood improvements. For researchers, this highlights the need for symptom-specific outcome measures and stratification in trial design. For clinicians, the results suggest that ketamine may be considered as an adjunctive intervention for sleep disturbances in TRD, though this should be balanced against safety and regulatory considerations. Importantly, the study’s use of both subjective and objective sleep measures provides a model for future research seeking to disentangle the multifaceted effects of rapid-acting antidepressants.

Risks, Unknowns, and Regulatory Considerations

Ketamine’s short-term efficacy in TRD is well-documented, but its safety profile, potential for misuse, and long-term effects remain active areas of concern. This study did not address durability of insomnia or anxiety improvements beyond 24 hours, nor did it assess repeated dosing or long-term functional outcomes. The lack of association between sleep and mood improvements raises questions about whether insomnia may relapse independently of depressive symptoms. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) currently restrict ketamine’s use to specific indications and settings, and off-label use for insomnia remains unsupported by large-scale data. Additionally, while polysomnography offers objective sleep data, its use in routine practice is limited by cost and accessibility. Real-world implementation will require careful patient selection, monitoring, and integration into broader psychiatric care frameworks.

Looking Ahead: Toward Symptom-Specific Interventions in TRD

The distinct short-term effects of ketamine on insomnia and anxiety in TRD underscore the need for precision psychiatry approaches that address individual symptom domains. Future research should prioritize longer-term follow-up, mechanistic studies to clarify neurobiological pathways, and randomized controlled trials comparing ketamine to established insomnia treatments. Policymakers and funders should consider supporting trials that stratify TRD patients by comorbid symptoms, as this may reveal subgroups with differential benefit-risk profiles. As the field moves toward more personalized interventions, the nuanced findings from this study provide a foundation for optimizing both clinical practice and research in complex mood disorders.

How we research: This analysis was prepared and reviewed by Dr. Alex M. Carter, MD, PhD (psychiatry and clinical trials specialist), on 2026-10-08. Primary sources include the original trial publication and registry record (NCT00088699).